0001493152-21-028035.txt : 20211112 0001493152-21-028035.hdr.sgml : 20211112 20211112084528 ACCESSION NUMBER: 0001493152-21-028035 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211112 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211112 DATE AS OF CHANGE: 20211112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 211400078 BUSINESS ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 BUSINESS PHONE: (215) 345-0919 MAIL ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
0000868278 false 0000868278 2021-11-12 2021-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): November 12, 2021

 

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

 

Delaware   000-21617   23-2577138

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

711 Stewart Avenue, Suite 200

Garden City, New York

   11530
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (215) 345-0919

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0005   PRPH   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 12, 2021, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 7.01 Regulation FD.

 

As previously announced, the Company will conduct a conference call today, Friday, November 12, 2021 at 11:00 a.m. (Eastern Time) to discuss its financial results for the third quarter ended September 30, 2021.

 

The information included in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

No.   Description
     
99.1   Press Release dated November 12, 2021
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ProPhase Labs, Inc.
     
  By: /s/ Monica Brady 
    Monica Brady
    Chief Financial Officer

 

Date: November 12, 2021

 

 

  

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

ProPhase Labs Announces Financial Results

for the Three Months Ended September 30, 2021

 

Company to hold a conference call November 12, 2021 at 11:00AM ET

 

Garden City, NY – November 12, 2021 (GLOBE NEWSWIRE) – ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, today reported its financial and operational results for the three months ended September 30, 2021.

 

Financial highlights for the quarter ended September 30, 2021 include the following:

 

  ● Total revenue of $9.5 million for the quarter ended September 30, 2021, as compared to $3.8 million for the quarter ended September 30, 2020, an increase of approximately 150%.
     
  ● 57,000 diagnostics tests were performed in the quarter ended September 30, 2021.
     
  ● Net loss of $4.0 million, or $(0.26) per share, for the quarter ended September 30, 2021, as compared to net loss of $0.6 million, or $(0.05) per share, for the quarter ended September 30, 2020.
     
  ● Adjusted EBITDA of $(1.3) million for the quarter ended September 30, 2021 as compared to adjusted EBITDA of $(0.1) million for the quarter ended September 30, 2020.
     
  ● Cash, cash equivalents and marketable securities balance of $22.9M and net working capital of $34.0M at September 30, 2021.

 

Corporate highlights for the quarter ended September 30, 2021 and subsequently include the following:

 

  ● Acquired Nebula Genomics, Inc., a privately owned personal genomics company, for aggregate price of $14.6 million.
     
  ● Nebula Co-Founder and Renowned Harvard Scientist, George Church, Ph.D., to Spearhead ProPhase Labs New Scientific Advisory Board.
     
  ● Presented at five investor conferences, including LD Micro, Benzinga Health Care Small Cap, H.C. Wainwright Global, SNN Network Summer, and the Q3 Investor Summit.
     
     
  ● Authorized the repurchase of up to $6M in ProPhase common stock. As of November 10, 2021, the Company has repurchased 140,769 shares at an aggregate amount of $791,000 or $5.62 per share

 

 

 

 

 

Ted Karkus, ProPhase’s Chief Executive Officer, commented, “As we recently announced in an update to our shareholders on October 13th, while the decline in the COVID-19 positivity rates continued through mid-Q3, it rebounded significantly in late August and September. As a result, our testing levels have recently increased significantly. Our testing volumes in just the month of October alone surpassed the entire Q3 testing volumes. We anticipate that this surge will continue through the remainder of Q4 based in part on our expanding customer base, including municipal contract wins and the opening of schools and other high-traffic venues, many of which will require either vaccinations or regular COVID-19 testing to gain access.

 

“For the first nine months of the year, although we recognized a net loss, our adjusted EBITDA was actually positive. We also anticipate a very strong fourth quarter. We believe that the winter months will bring about increased testing based on the winter flu season gearing up, for which there may be increased sensitivity to distinguish between the two viruses. We are also building a sizable customer base of independent pharmacies and concierge services that we anticipate will provide consistent and growing testing revenues for our diagnostics business.”

 

“We are also proceeding as planned with our integration of recently-acquired Nebula Genomics into our ProPhase Precision Medicine division. We are confident that combining Nebula Genomics’ comprehensive genomic testing with our CLIA-certified lab capabilities will lead to faster turnaround times and lower price points, driving additional demand. We also plan to offer low-pass genomic testing at significantly lower price points. This will allow us to leverage our distribution network of more than 40,000 food, drug, and mass retail stores to further expand direct-to-consumer and big-box retail distribution of Nebula’s genomic sequencing products and services. Each of these initiatives could significantly grow sales as we look forward to 2022,” said Mr. Karkus.

 

“The Company continues to be active in our recently announced share repurchase program, which reflects the Board of Directors’ confidence in both our current business momentum and the future opportunities before us.”

 

“We are also continuing to evaluate and pursue additional strategic and synergistic acquisitions to build our precision medicine and genomics research capabilities with the help of world-renowned genomics expert, George Church, co-founder of Nebula Genomics and advisor to ProPhase,” concluded Mr. Karkus.

 

 

 

 

 

Financial Results

 

Quarter Ended September 30, 2021

 

For the three months ended September 30, 2021, net revenue was $9.5 million as compared to $3.8 million for the three months ended September 30, 2020. We recognized higher net revenue for the three months ended September 30, 2021 primarily as a result of an increase of $7.1 million in revenue related to our new diagnostic services business, which was offset by a decrease of $2.5 million in customer orders from our consumer products business as a result of the demand and inventory levels of third party contract manufacturing customers.

 

Cost of revenues for the three months ended September 30, 2021 was $5.5 million as compared to $2.8 million for the three months ended September 30, 2020. For the three months ended September 30, 2021 and 2020, we realized a gross margin of 42.0% and 27.1%, respectively. The increase in gross margin from the prior period is principally due to increased margins generally associated with our new diagnostic services business.

 

Diagnostic expenses for the three months ended September 30, 2021 were $1.5 million compared to no diagnostics expenses for the three months ended September 30, 2020. The $1.5 million in diagnostic expenses for the three months ended September 30, 2021 was comprised of network providers expenses associated with our new diagnostic services business.

 

Sales, general and administration expenses for the three months ended September 30, 2021 were $5.9 million as compared to $1.6 million for the three months ended September 30, 2020. The increase of $4.3 million in general and administration expenses was principally related to growth in personnel expenses and professional fees associated with our new diagnostic services business.

 

As a consequence of the effects of the above, net loss from continuing operations for the three months ended September 30, 2021 was $4.0 million, or $(0.26) per share, as compared to the net loss from continuing operations for the three months ended September 30, 2020 of $0.6 million, or $(0.05) per share. Net income from discontinued operations was $161,000, or $0.01 per share, for the three months ended September 30, 2020.

 

Our aggregate cash and cash equivalents, restricted cash and marketable debt securities as of September 30, 2021 was $22.9 million as compared to $8.5 million at December 31, 2020. Our working capital was $34.0 million and $9.6 million as of September 30, 2021 and December 31, 2020, respectively. The increase of $14.4 million in our cash and cash equivalents, restricted cash and marketable debt securities balance for the nine months ended September 30, 2021 was principally due to our receipt of aggregate net proceeds of $40.6 million from the issuance of common stock and warrants in a registered direct offering and public offering, and $10.7 million from the sale of marketable debt securities, offset by (i) capital expenditures of $4.2 million, (ii) cash dividend payments of $4.5 million, (iii) issuance of a promissory note of $1.0 million, (iv) payment of $9.1 million related to business acquisition, and (v) cash used in operations of $9.0 million.

 

 

 

 

 

Conference Call and Webcast Details

 

Management will host a conference call at 11:00 AM ET today, November 12, 2021, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

 

Participants can register for the conference call by navigating to: https://dpregister.com/sreg/10161532/ef2e0ef568

 

Please note that registered participants will receive their dial in number upon registration and will dial directly into the call without delay. Those without internet access or unable to pre-register may dial in by calling: 1-866-777-2509 (domestic), or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into ProPhase Labs call.

 

The conference call will be broadcast live and available for replay at https://services.choruscall.com/mediaframe/webcast.html?webcastid=ddkWfCfc and via the investor relations section of the Company’s website at www.ProPhaseLabs.com.

 

A webcast replay of the call will be available approximately two hours after the end of the call at the above links. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code #10161532.

 

About ProPhase Labs

 

ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a diversified biotech and genomics company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing. ProPhase Precision Medicine, Inc. focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.

 

ProPhase Diagnostics offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories. ProPhase Diagnostics serves patients who may have SARS-CoV-2 (COVID-19) through both saliva and nasal swab methods. Critical to COVID testing, results are provided in under 24 hours. ProPhase Diagnostics also offers PCR (polymerase chain reaction) testing for Influenzas A and B and RSV; as well as antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.

 

ProPhase Global Healthcare, Inc. was formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.

 

 

 

 

 

ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements® brand. ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products. For more information, visit www.ProPhaseLabs.com.

 

Forward Looking Statements

 

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including statements regarding our expectations with respect to Q4 COVID-19 testing revenues, our goal to build a sizable customer base of independent pharmacies that will provide consistent and growing testing revenues for our diagnostics business, our plans to provide genomic testing with faster turnaround times and lower price points resulting in increased demand, our ability to leverage our distribution network to expand direct-to-consumer and big-box retail distribution of Nebula’s genomic sequencing products and services, and our ongoing efforts to evaluate and pursue additional strategic and synergistic acquisitions to build our precision medicine and genomics research capabilities. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to general economic conditions, the scale, scope and duration of the COVID-19 pandemic, consumer demand for our COVID-19 testing and other lab processing services, challenges relating to entering into new business lines, the competitive environment, our failure to obtain and maintain necessary regulatory approvals, our ability to continue to ramp up our labs’ testing capacity and execute on our business plan, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings.

 

Media Relations Contact:

Jules Abraham

Director of Public Relations

CORE IR

917-885-7378

julesa@coreir.com

 

 

 

 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

   September 30,   December 31, 
   2021   2020 
   (Unaudited)     
ASSETS          
Current assets          
Cash and cash equivalents  $8,533   $6,816 
Restricted cash   250    - 
Marketable debt securities, available for sale   14,114    1,639 
Marketable equity securities, at fair value   214    - 
Accounts receivable, net   10,680    3,155 
Inventory, net   8,510    3,039 
Prepaid expenses and other current assets   1,602    1,238 
Total current assets   43,903    15,887 
           
Property, plant and equipment, net   6,454    3,578 
Secured promissory note receivable   3,774    2,750 
Prepaid expenses, net of current portion   460    2,084 
Right-of-use asset, net   4,484    4,731 
Intangible assets, net   11,562    1,234 
Goodwill   1,385    901 
Other assets   608    240 
TOTAL ASSETS  $72,630   $31,405 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable  $2,394   $3,771 
Accrued diagnostic services   3,260    - 
Accrued advertising and other allowances   344    463 
Lease liabilities   676    329 
Deferred revenue   1,517    - 
Other current liabilities   1,741    1,731 
Total current liabilities   9,932    6,294 
           
Non-current liabilities:          
Deferred revenue, net of current portion   106    162 
Note payable   81    - 
Unsecured convertible promissory notes, net   9,995    9,991 
Lease liabilities, net of current portion   4,252    4,402 
Total non-current liabilities   14,434    14,555 
Total liabilities   24,366    20,849 
           
COMMITMENTS AND CONTINGENCIES          
           
Stockholders’ equity          
Preferred stock authorized 1,000,000, $.0005 par value, no shares issued and outstanding   -    - 
Common stock authorized 50,000,000, $.0005 par value, 15,652,724 and 11,604,253 shares outstanding, respectively   16    14 
Additional paid-in capital   103,807    61,674 
Accumulated deficit   (7,947)   (3,631)
Treasury stock, at cost, 16,652,022 and 16,652,022 shares, respectively   (47,490)   (47,490)
Accumulated other comprehensive loss   (122)   (11)
Total stockholders’ equity   48,264    10,556 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $72,630   $31,405 

 

 

 

 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Other Comprehensive Loss

(in thousands, except per share amounts)

(unaudited)

 

   For the three months ended   For the nine months ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
Revenues, net  $9,472   $3,840   $33,885   $9,351 
Cost of revenues   5,495    2,798    16,515    6,615 
Gross profit   3,977    1,042    17,370    2,736 
                     
Operating expenses:                    
Diagnostic expenses   1,478    -    6,117    - 
General and administration   5,938    1,552    14,713    3,875 
Research and development   208    57    416    181 
Total operating expenses   7,624    1,609    21,246    4,056 
Loss from operations   (3,647)   (567)   (3,876)   (1,320)
                     
Interest income, net   230    39    531    53 
Interest expense   (296)   (41)   (870)   (41)
Change in fair value of investment securities   (265)   -    (101)   - 
Loss from continuing operations   (3,978)   (569)   (4,316)   (1,308)
                     
Discontinued Operations:                    
Income from discontinued operations   -    161    -    161 
Net loss  $(3,978)  $(408)  $(4,316)  $(1,147)
                     
Other comprehensive loss:                    
Unrealized loss on marketable debt securities   (33)   (8)   (111)   (2)
Total comprehensive loss  $(4,011)  $(416)  $(4,427)  $(1,149)
                     
                     
Basic and diluted earnings (loss) per share:                    
Loss from continuing operations  $(0.26)  $(0.05)  $(0.29)  $(0.11)
Income from discontinued operations   -    0.01    -    0.01 
Net loss per share  $(0.26)  $(0.04)  $(0.29)  $(0.10)
                     
Weighted average common shares outstanding:                    
Basic and diluted   15,439    11,604    15,055    11,593 

 

 

 

 

 

ProPhase Labs, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

   For the nine months ended 
   September 30, 2021   September 30, 2020 
Cash flows from operating activities          
Net loss  $(4,316)  $(1,147)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Realized (gain) loss on marketable debt securities   40    (2)
Depreciation and amortization   2,044    253 
Amortization of debt discount   4    - 
Amortization on right-of-use assets   247    - 
Lower of cost or net realizable value inventory adjustment   -    17 
Stock-based compensation expense   2,438    679 
Change in fair value of investment securities   (164)   - 
Non-cash interest income on secured promissory note receivable   (50)   - 
Changes in operating assets and liabilities:          
Accounts receivable   (7,327)   (1,015)
Escrow receivable   -    4,812 
Inventory   (5,036)   (696)
Prepaid and other assets   1,639    (30)
Other assets   (368)   - 
Accounts payable and accrued expenses   (1,749)   470 
Accrued diagnostic services   3,260    - 
Deferred revenue   1,461      
Lease liabilities   197    - 
Other liabilities   (1,292)   835 
Net cash (used in) provided by operating activities   (8,972)   4,176 
           
Cash flows from investing activities          
Business acquisitions, net of cash acquired   (9,066)   - 
Issuance of secured promissory note receivable   (1,000)   (2,974)
Purchase of marketable securities   (21,527)   (4,317)
Proceeds from sale of marketable debt securities   10,701    3,839 
Capital expenditures   (4,258)   (222)
Net cash used in investing activities   (25,150)   (3,674)
           
Cash flows from financing activities          
Proceeds from issuance of common stock from public offering, net   35,135    - 
Proceeds from issuance of common stock and warrants from private offering   5,500    - 
Proceeds from unsecured convertible promissory notes   -    10,000 
Issuance costs on unsecured convertible promissory notes   -    (10)
Payment of issuance costs in connection with ATM   -    (66)
Payment of dividends   (4,546)   - 
Net cash provided by financing activities   36,089    9,924 
           
Increase in cash, cash equivalents and restricted cash   1,967    10,426 
Cash, cash equivalents and restricted cash, at the beginning of the period   6,816    434 
Cash, cash equivalents and restricted cash, at the end of the period  $8,783   $10,860 
           
Supplemental disclosures:          
Cash paid for income taxes  $-   $- 
Interest payment on the promissory notes  $750   $- 
           
Supplemental disclosure of non-cash investing and financing activities:          
Issuance of common shares related to business acqusition  $3,608   $- 
Net unrealized loss, investments in marketable debt securities  $(111)  $(2)

 

 

 

 

 

Non-GAAP Financial Measure and Reconciliation

(in thousands)

(unaudited)

 

In an effort to provide investors with additional information regarding our results of operations as determined by accounting principles generally accepted in the United States of America (“GAAP”), we disclose certain non-GAAP financial measures. The primary non-GAAP financial measure we disclose are EBITDA and Adjusted EBITDA.

 

We define EBITDA as net income (loss) before net interest expense, income taxes, depreciation and amortization. Adjusted EBITDA further adjusts EBITDA by excluding acquisition costs, other non-cash items, and other unusual or non-recurring charges (as described in the table below).

 

We use EBITDA and Adjusted EBITDA internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s ongoing economic performance. We have chosen to provide this information to investors to enable them to perform more meaningful comparisons of operating results.

 

The following table sets forth the reconciliations of EBITDA and Adjusted EBITDA excluding other costs to the most comparable GAAP financial measures (in thousands):

 

   For the three months ended   For the nine months ended 
   September 30, 2021   September 30, 2020   September 30, 2021   September 30, 2020 
GAAP net loss (1)  $(3,978)  $(408)  $(4,316)  $(1,147)
Interest, net   65    2    339    (12)
Depreciation and amortization   926    3    2,044    13 
EBITDA   (2,987)   (403)   (1,933)   (1,146)
Acquisition costs (2)   674    -    674    - 
Share-based compensation expense   934    283    2,438    679 
Non-cash rent expense (3)   72    -    443    - 
Adjusted EBITDA  $(1,307)  $(120)  $1,622   $(467)

 

(1) We believe that net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most directly comparable to EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA measure the Company’s operating performance without regard to certain expenses. EBITDA and Adjusted EBITDA are not presentations made in accordance with GAAP and the Company’s computation of EBITDA and Adjusted EBITDA may vary from others in the industry. EBITDA and Adjusted EBITDA have important limitations as analytical tools and should not be considered in isolation or as substitutes for analysis of the Company’s results as reported under GAAP.

 

(2) Transaction cost related to the Nebula acquisition.

 

(3) The non-cash portion of rent, which reflects the extent to which our GAAP rent expense recognized exceeds (or is less than) our cash rent payments. For newer leases, our rent expense recognized typically exceeds our cash rent payments, while for more mature leases, rent expense recognized is typically less than our cash rent payments.

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 prph-20211112.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 prph-20211112_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 prph-20211112_pre.xml XBRL PRESENTATION FILE XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000868278 2021-11-12 2021-11-12 iso4217:USD shares iso4217:USD shares 0000868278 false 8-K 2021-11-12 PROPHASE LABS, INC. DE 000-21617 23-2577138 711 Stewart Avenue Suite 200 G arden City NY 11530 (215) 345-0919 false false false false Common Stock, par value $0.0005 PRPH NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Nov. 12, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 12, 2021
Entity File Number 000-21617
Entity Registrant Name PROPHASE LABS, INC.
Entity Central Index Key 0000868278
Entity Tax Identification Number 23-2577138
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 711 Stewart Avenue
Entity Address, Address Line Two Suite 200
Entity Address, Address Line Three G
Entity Address, City or Town arden City
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11530
City Area Code (215)
Local Phone Number 345-0919
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0005
Trading Symbol PRPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://prophaselabs.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm prph-20211112.xsd prph-20211112_lab.xml prph-20211112_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "prph-20211112_lab.xml" ] }, "presentationLink": { "local": [ "prph-20211112_pre.xml" ] }, "schema": { "local": [ "prph-20211112.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PRPH", "nsuri": "http://prophaselabs.com/20211112", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-11-12to2021-11-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://prophaselabs.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-11-12to2021-11-12", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001493152-21-028035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-028035-xbrl.zip M4$L#!!0 ( *U%;%-S*3<*:3$ )), @ * 97@Y.2TQ+FAT;>U]:U/; MR+;H=U?Y/_3AS$R1*MFQ_ (GF9Q+@&0XFQ F,'MJ?SK5EMI8$UGMT0/"_/J[ MUFI)EBW;"&+9$FA7S0Y@N;6Z>[V?[WZ[_GS^OEY[]]OIT0G\R_!_[Z[/KL]/ MW[][K?Z%3U^''[_[\.7D/^SJ^C_GI[_NC:3COV%Z:^JS:VLB/'8A[MA7.>&. MIOZ@L2OA6J,]^")\]?*QWWO+)MR]L9PW#!]MO66^^.XWN&W=P)\,X?C"W7O_ M[N.7B^ODRHT1GUCV_9N'UJ9G/>L?H4"!E3Z\_\49>M.W[UY_@+WCNO#/91[ MN];-V-\P[*??Q];0\NNUP:"IY[^%LIQ_PY=3VD#\AZ'T?3D)_Y;SELX^?V)7 M7X]_W1/?!X.&_G^MEM[\:WJSQX[.KW_=VXM>,A:($&]8K]5L]Q"L.\OTQ[!* MK]\\Z-%*U65N%?B2@GWIRLLQ]T2]=LZ''CMR'!DX!JSRT7*X8UC<9E^%%]B^ M5](-CJ1;K_ECP:['KA#L,SPR]MBI8PH3OC;UQ60H7-9I::S=:NNLI+M\=Q93 MSUE941'V<"PG4^[WPRKC/=/U- MJW7TF9U>;V?_?P6>;XWN-WD T?65#.Q/W#6%4Z\=6_Z]QB[^PWYQ3.Z-WRZY MI_U/YU\^G+*+TS^O_CS[>OHJ?C3B00Q9D,;.'*/)YB <GY^=7ET?'9Q:=?]UI[]/OE MT5NKXA85MZBX1:[ 'IGX>F$J"$\_G%V?'!$M[^O- MSJM'&P&+[(&'R\^MW&KJ*U=6<*QD"*SB"!5'J#A"GL >[&/I3J7+??$TURY>MQ<,/4 7 M0!7[OO+U5K[>8G#R'?MZLX.9,R8?&<#)W4C5NQ##P.;L4QBU4U%!,._8U 5V M3WY6>>< K8/=YE&$+AW@0^; ;VY<<0-?P"^& D#OS@S!%VW#_>#=5QI;D36V MPA"V(F4%W[%L?,0X/HAFE,A?@6:)BG_C[BUW07(;%HAGR_,U('WIW@AV/ Y< M8ZRQRW'SI(E!>W8U%=P="V[.)PX01.'W1Y;!CLQ;RY/N/?L@8>6*SBLZK^@\ M5SJ_=(6'>6&A! ?S:63="E"T;X7G@RB>97+!(DK]1L/K_(1]M@Q7:NR#WG#M*AV:?; EV'0!T<0%@^FC) ML:M@,A$N1FA#,%"__[T#ZD,(!3Y@^2_;4U/Q@[+R@TV:'=NU3"MDJ83'.NLO M\,?2A3\DV+8KIJC[A4DVP92R=OJ?,9@?:WY@[$VDPX"U&]^:[(@"?;/4TS@L MB,N%R<4,OI=8VF1ZMZ4=] AW.+.S&X,A=D$M%:?K,>#@8Z)!Q2I[#7[ M[5GD,&_7(/V_;CF[<2K!!OZKT6 ?+6&;;]@EOQ%O80%TIQGX1=9H1.AUK,'F_.D;9FPDYG_*NFO6O1G1=G!JQQ1"PZK MU#83;&@)X^6H^]@ UFW1]YPN,<@>8\A4OK5D+QFY<@CR M!LNS-N1A?O*6\HD#K.510/NK,ODW6$E2-A?^-"VV"HZ8PK M1T0I=,=? M_GUVTM ';"H]"R"R_'N&81GTNSJ^Y00861_#%=^,V<0R&[]WP-CS :HA^7U, MYL$YHH.&AV$89B-41\$-G"PYA>+H3;->@RWQL/9"([ QNP^M1EO<"ML#67Z; MV'&4D[OPDB;[DOCFK;0#O"!X,UXF;8KJ.%"ZAZ? N"UARU[@3KGGX?W@4^A9 MK@"L^,X"$S8ZGOATE(HS 7L6W6'P\M^[ M0!^>NJ\I=WV\%MRS^ YZ"]K*]9H!$$LP<.G!I!4]"1QZNWJ/RPT?WNJHD"B^ M2$Z%@\_!:SQC+*6M/I+PF0B[Y> M$Q9][Y8;AN5P+)'Q4!\"C2FPN3O#D>B< .=N.&*A <:_URP=B98T9AKRA8]1 M">3(<@'A':3FL'()[A<_N!<! *,L.D6"BTDS=Z!/ M [X%W 82#+F"4"1A>S))%[Q> T7K'K1U5P)6C& U(+LP=DO?& K; LJ.* A) M!]6 "%S"PJ&+*,6!G_@)BH]035&0=)+?'MD!\^ Q^.L-[)0H*9BJ )%";T1G M.!1^#Q DV8AP8B8'.&Q:]([ \L;PG'\GA'J-?R?9K>4&7L0*W'#OP\"RB3PY M<*1_*"EACH+K-;@ I/\I!J[!P)@"5YYP U,6D#R!EN%G9"&><&\MK,NED[F; M8S=T*E-7WEHF&D0 ,ER/HY@I"-L[HL#P>,(R"A4YQ]M,I$[7:\/ ^0 "OW% M)$KK#6->,-J^R M9 S(89A5D<..&9BVWFQHOL ME\@LPC.2HY$'@ _AW1AUF;VKG3@[>%7L0B2M!=39D2LGRCJ*;/_8;(_MI(7M MJ,C.A)12QZ0D/FKX1XM\ MI5@PTY#GG;G:<)_KLK:'/]@_0Y\='@8*XJ%KL4 P"SDQ% M(&Y<+.)7QXJXV6TW6S^KIX$0?]80LZ>"?!,8[[L>S[SXY#^8^SZ1"\($Q [0 M@2UG22 !#W]W*(@&Y&\&%"J=Q0+4E\E))EQZA'N>!'7!3[IE'Z+WBE!V2"@G M\<74:VC#.][C:07C1#_I"6*9:SND+MDR'V%[G6M7@OY4^AOFEB.12XTQ*(?POE><[!2 M0.BS@KIH;=06'UZ\-<^KPWXPG23>9]D/8G:2><^4,#@/5]X!_F).!94*.L*> M?9%\CJX< ?(J=^-(5+A?/MP_\K#U*VJ_H3K=I M>;,DKL3;:7=ZG_*>U5JPE+ZL95)& 5?1RJJM])I=W-!6J.9+ )KZK$":VFE0 MULE"7PW2KGW7,I AQD\E&FV88N@GNVV0+;N23+#_QC))0I'^GPZ3=HC/3H01 MKJ%' @.3^1:[=M#"G40G,0+QIT%"+JT$"I],OJ9>4Q;(:I,BJB+O)N44V=\; M.\*P80G8]B%E);.VUK*A)49,%*JUILJ5$5\YLIXPSR3LQ=9*2O+(3K(\+U#0 MP#/)B@O:Q1UW78[M5S#!#W, ,?T(^9O*25 9%I1+00&^H0WB,_J;2G'X26\U M#]*OQ80!2I&8/Z9Z;79.6L)ILF^]BO&!!+QI820X:C+7GG'#?8L>A5O ?!=@ M#^CFN)]0#QGU<&_N87@Z.@(Z/SRS"?Q%NO?UFB/]$"&2?>SVK=M7T:)ASUH] MWF'"1S3SS\RBF>I0]F]#&(,P)33!D-6"K703@_(QH2?4FG2J0&$5**P"A56@ M<,>L"_9Q'->TUVO'6*B.G/M/,03&C;H+)MV5,XA84D/P,W> 'Z'0K=64+\15]Q: ,!L-D@T"R1T'E#:]:R^AER"8:\R MT%= >Y134BV:]=K'J-$8QE%"0./L2VQ53:NCON-I84ZZ2GF'%S 0?QZ*_P:\ M%_[S, W54XZ+\J4)E1*_UM2O77)7Y>/#1==K!G=B13BVC1=Q$%16A]]:H(BK M3+BH^1S;W"F/?7_JO7G]VIQ&T#1!?7_MP6^O]198]+U.^[48M45+C'K]PQ+S MXM(;XY>V"E:1.4&I]@E+:IK KJ@4"\PY*I01%A5QV&@B. &QKV J(_P+/:5D MI^'WZ$EEF%'!7.B#(H1$7R<6U9A@GMP#M[H&YBGBOU(I#1J,JH@+W4"!0T:9 MC\4*HA$C/);11! !DN/:V%N1Z8W#?K]Q<'#0:/=: [9OR@ER-.,5^93T1E=O M-SKZ0:/7U3M@0-'[N$H#?86U@%A$!VMAP:(WIBSSZ"T+ SC0,'("K$E4$;YP MDYXQ%F9@8Y*RC^5U/MR(N(*A6G@..@!N3'<^-B"6,LW< C_$'FBRG) M?.3RB7A]IQ3%YMB?V/\3_F*9OYKFMS]'QR,#[B<)U!ATXL5>^1:(,1JQWP7L_"].OX+.[N[IH1\B/N(]C9(,EIWEGIZ62;&S@" MS36+1: MAX>+PH*61L?:3;@R<@I0TO\[TGDJ1KZ+], 9E[0\$/OE!N.Q&@JZM]<@#V'MLI1FTKU,G.08?, M&=,KPF+SL2LGTL.'*&?NY.)(A;WH+.70YZ0;4WAFL4P6#5ZJFL*4.9-:L*)U M 0=M^10)\E2NJJK2HV)W@W9 7X(=P GX^!B%UUS+^Z8^ D"BU3"D0^$S+(VE MX!R&^[40=([9J0(;B-&.,$5C$OA* YK?,MHTA*18)(S"";1'5U4I5LZ4'?&C MDT32'(4&D>60$L\PN$@J#':AP;!),@M'89-"P3@C!ZXVYC9S%>:*4"VL7XZI M\"39_@"70*,1T(9B@<"22$.A+C-71U^O&L?RWXTVVX_(^E7Z"_(=0?5%?F MJW^_K=>H4!NU/8]Z30!5*3L*?AY*\_ZU-<&>,]@8@P;N(9O%"X/'Z/076\ , MQ;W$M:\;"&'$#DN'LZ4G-=4T-VRQ:U#R#@D=3!T(AR7"5:( I^)\X!J<1!<<3/06>"9JLCVIWJZAV M%=6N.BB6*(Y=>EE 9B"VPS6% 9*;\HJHMX%%+M7(1"(-)8QDTL]S16!:HJN, M^A"SM>+<+D\H=\Z7Z^-9>=J,W<>5:B .J(V-\#G:4L%T:E-X=$Y[7_)QJ"&A MA+K^%[N:??#NZH_+][^XX@9N"'\$]80: ,4:% ]S^T)YY,U:3:#Y@V[423Q5 M+)&=M=!9A/IHA7(.!219-0M6FHH3TS95010U_;$2&6O M1@ZVI6T,V94\SB )%OWN- 65T9, MHOY354N'+3"I9]!]MB9O\%!$>ANC:&67U6M;;?NFL]N.^H)]8Q!=7A#/N)JD"6.J:[L0 00(]JLM\ JVZQ M2;,7P&L75JK7$DN!HB'M6\&^88\I%;=RU,_H!(4CQZYJ+K(I/]8EE+J!"IAT M0Y#12V7P0&DU02)'C;J64HM##/"Y%I4%H L7*5.J]FQ_*;]JR.96[YN\P:%[ MU@MA30 7C]0$1*,C%?()0%7"-_A773R6+:H$#6X+.#1#3M4= MFL&LP^5\\VGX5, :VDRG#+L91%PCQ==F)X-9X#JS9M*2N7PRQ>D8^ AL+6ZA-_/- M3X$7^_?T1D&-Q$746CK>![)2+>ZAAS<<(YAM4;??$&DP9P;S:?#?L.KER'$0 MY;Z**5$Y+/T119_>:OQ+8V$S%\"Z)9__'KH4[\.;N3H]9B,+[04OIU2"2ME: MK?9B'(IC[Z,H<^08%23#?U-*I?=_ QOI^ C,OC&?E [\J",F95%XV#SL&FTV.W0--_O/\+J8#_/T." 43)O^]> M_U$^6GZ".[U7N=,K=WKE3J_0&+B3E=#O%O"B=_4 7U[&HLQ#;%20 M(S3LN4X>E:@E1SBQT'M5TIVN#B#D)HJS<:F%^:6+"N62>[,;NXRUH M029ZT6-Q31KAAK>?1?E4'6_GP5T*6TA)3[K60FVWM9GMYHD>&R>#_3\<'ICH M*WWU:&+-#,NR%Z]>*OL!+HO5N3?#_7:KJ[4[AUJ[UWNU8ECSPL:.KJY.KZ_6 M;VS)9I0UM/SNDL_1X/@L#RY;L$C0_-#5_*GB-!GV\@B@5- MWA03,4)\R[TNPP[TF!\G>]$EC<9M7LI<;XKBFX4 MGYC3$'U>V21.6RAJQGYI>1^AWM5TO5N4"]6U?F=0 ,'YZ)M$/NS?S]^ECT%B M'*IK![E?8[LX=UA*HCPRJ*K!"_MPX)U26]G<$;ZE]0\+PT\[FM[KE8;\SJ(9 M%UNY*5!M] )=5&NK?')#=+;2*7'IBBD."9WKXQUF82^U6-8Z$M8KC0]Y++)K MJ8];:2;B6NV,_I"L@)3Q% "5-G(*6S&<5R+NM<3NM,\-1[L=;=!*V7$O#TE[ MVN'AP>ZQ= WW+;#KI%C0;,F_=NEB5V<_3/=7"?%H&TQ5YN@6])2^UNT5QA;H M:+V#%)O?K9Z2?CO5>P@ST02<4=.^F2F0_S$='!3FSMK:P6,]/%LCKGDM40W^ MP%82H?S%?&1+.GF?4+=?&$.@K;4.'XDYVR>PKPAK0XX:5,^ .M)6.&%7ZS[V M;/($YJ"3BOH6@JK.')\[-Y8J?$']=3N.#UWK]5-VT.[\CNU.0_W69DSQ,I]!NYLU266WTO6![)/E M6-L.G15?KH_.V7Q&QIIU5ZSRZ$ND[S%3!B!BEN3X9(K=_OC"X3T?M+5^Y\&K M;J_(1\J.A"_E/#NZUFVEQ,BFSG.C7+[ WHEB05, 'K;W_OSLZ,/9^=GUV>D5 M.[K [WXY_M=O7\Y/3K]>116QI[__<7;]GR(>8;&@V7)RF6W%5?E%/(UB05.$ MN%PB_CWE]S_@\4K)F:4NB\X@;[,\"QSH="N"T9'Y@MR .N^F1A;G[YUL%\?A M5=;L$KH\;M++O?GV%1QG2&$M4_XWV2V./ZR?BB\6EO;.J8GU%J5:_R"5B+JS M"$Z[A'DF6(0T$BX&=<+N4_D[TWIZ*E+\$GCDCU#6 ^XU8[4Z65X_DZX==+-6 M?SU?;YN^+!I22'];9IR=SP1Z5C@[T :=*F6MK[73=LON4]8*;-H6"YKMQ[TO MI--8PA#>%/%TB@7-#I7]1JLP-H#^V$!],6R "TSB^C%_5N8C.GRD M)ZE2_O?>_^%X8>:=(1UZ*>:@+&3A;2<;!32<07%R(0"8;3HF\R[N2+E/'F*I MY=41X1![E:;M< R]=-7CU3C^E$K\X;&VWM,-NRB6_>^9:8&.R6- 4(KGF^,OGSV?7GT\OKE5RS?&7 MB^NSBT^G%\=GIU6SINT:307>9[&@V4%EF"^-;V.@(>'&4QA4IX\BGD^QH-FA M8^'2C7QX'EX@XX$_ECA*VF2ZUFJUZ#_V4Q/^Z8$&%;9H :M4JEZK'K,\C_(U M,$M8WL& MM.([$2HD[E^+1FW1F,'\O:Y%08?']A;:99K<;/04EHHV+ ?'Y5A@#>7OK^]H MAZW"Y(#T 9$?6U-<##H^,HQ@$JB9T:8868:5N_MW_T ;=#-EH_2QE MHJ]V3FC7."\MP-&MR&^IVYDA/1\8:I\8:JO=5@QU]JMBJ-MEHOO= ZT[R)"] MFO_5/A*2(A#C2O]2DD9GPW)=,1:.A^/2;.D] Y?3OMY^NAL[U?6YC/M_>H[6 MKCG4 ZY1[T'+KKS7U@6:[U=^?;VE]7J;<1@7P&?W0%'OXZOEUKS[61:J5H6_ MFSW/+17^AG/.2C_F9OUPNWXUW"YQ\>^JX7;;F$2[=I#=%F@E227%&WN7\0 R M3O=;PQG*P-8JL*MQ?IO9VZIQ?E?Q5'I,#/PR%6XXLQKWK>K!CN=<#.?D8BCE M&:R8^O=L9OWM!XG15Z7QIS%N8&9[(5-74QM?D,S&,NY^>KFM\@TGN@$ M#25B=_G8NZ^J&F^^'&CAJ_F,BUM\/*[2Z1ZDHD-%&W6W O:.=IAN=UD6V 'X M=-_:D@ _T#J]%"\JQHS!!;9U+#TJT0JK8)]!-+>G==,U?B\N*M;6#@95MU^] MK_7T"AGZ6G]#IU"8RJ=/KO0\+"(>62DUH7P7U-$&!YL90%3F4]"U5K>JJM4/ MM,[!9IJ4E_D80(!U"I#5457Q5-!L')KM5SB%@1;G)AZJ5'4GJJ I9]G7R:PU M9^0KG4?.]\N/V *4S[6U_27V0QU8S4PGX0#?-FFX#;X*B.=] M7#UMD![,NZN[T[5>NIW.SH#I:@?Z(YM6YP=-1SL\*,NH]I7&^E?A">X:8\)S M4]P*6]*@U&=@I50CM=[W*L]%-UW$^^+.0$_W1BRWBU%5$,F4Y53^JSK0^NVJ M< A; &RFPU*93Z&M:^UNQ;VZ6JL(160_W,L0TV79R)63B'%)YQDP+*R73Q?N MOZ@:W5[_9>\?#:&G$^AS. %=ZV3.\5IY KF-LRZNJ[*"IBS0;&E^Y1FF6 K/ M9Y9CR(G82N?Q=KHF>69.A, MMH5^.MG[).4(Q6$Z):/@A[%;.^1XS)T; 1R6C;@5=N'#/%/+N04<1N@G*:B;R_.@;"OMWZXBU*9][\9#"B,\W?F1S&DXUM.@![@ M9^92&:1S&EX2QN[W^D]W_SZ'_7>US@_$K9[#">A:YP<"N'DH6@6VSBMHR@+- M]HW3$\L+Y:0P$UT]JB33"IJB^P-7JH!GY!U42J"9Q._GI 96AIO>K^:T5UBP M*2PH<@O9"^$O[=C]4EJ99C-Y']/*-&4#O9BC[#YL-U4'F>D@LQCAU5%F.4I= MTQ].$GK"458&?@5-L:#900'IBND?E85?05-:"_\/QQ7P'$Z/0UQFTL$.I-^$ MST'L,%,,GUF0NI-*W2?WS*3ZGW_\,CGG8?FXY&P5!ATN,G<6U& MR]^,2K_<%&H]C*/M)^-HX;>?V0Y\CIO7NNVLMMLSW#Z:K@\F(SRT_S@2"5,Z6"IH#< M=O7;,V;)/O*04DK5,HVIU6SG6)Z2$83T8,2M@]#.4,V5,PAIHVT[*NJC_7U5 M1L^+R.4 NJQ2>BHTV!@:;*M7X(ITG9E^6'8OQS*9_7)\/("/#S9=>LZ[3VLJ M+VGW>M:9Y)5[KX*F)-#DYM[[DQ*S0#'GL!Z.Z0:]?2(=)04])@/?\[F#U%.Y M3"IHBN8#?%JOW%"$I=R%NQ)]C]#$'Y1_>D_KIMO.9!: V2R24AP$-IU\NA;X MC ZBI[5Z#[;,> D'H6N]P8-Y69D.(F9FKVEZ]?OR3^'>+/!_!9YOC>XW"OT\ MP #R?S4:[*,E;/,-NP3-Y2U\]>] . 9\Y8 U&A$&GIS].P) 01Q?=1\O^N'Q MK_E-*)_?X&K!Z,OI,HQ,8'%BZ32F1ECZ[C69^^ZG%\]<3>O\7+4?6P STI*$+E0\T;!5E=-&M0"F:2T MJGPV<_;Y$[OZ>OSKGO@^T_VNU].9?TYL]=G1^_>M>3%_CL)*DUVJVB5-' MJ-_K-P]ZBE.4\C9+C8J7KKP<.4:35.NK8.A9IL5=RNLNY=Z. MI6-B&T"S7H,?22APM)BO?/@'^ZMYV&[MF'MC]M&6=V7=YK[EU&O^6 8>W)OW MJJR["!P>F& MFF7=P6H^D)L>DN4@]K)9[ZL=GW/GL[Y(41=/[*%WFCP5S+$>P":PZ]I@ XG_0,Z"O*'5\H@MD>X?87L27-8&_ M3,>\]_Y*3($M#H7+.BV-M5OMK*'!!TXOS\UO#(-2F\_:1GQ3J)-?LX.]]R3B M1BCBYN8>.#>,&[YU.U>[52378[&@R<41&K+T/G+T].M7M:,(O]7^>;WG)I(7 M2]=.Q>VBI_L_+P_0+2W#7_N*5$QR)W OK7G/ O?VDP6/3'3 *-74E\P5AG0, MRQ;8?ETE.L!?\6<#*7KJREL+A!P;WK/] /1<9CFOEA)W%0(J;I@#9_]Q56&[ M?\/Q!K,7VN9U@-W"=.)/UR3NC%PSCMX54R!;BU(EU=#2B00@_MG*R-*VUNJF M0B>[NKKV5@<&_!@)'B4N"9T"1&^4_QHXN0^^*,R-E7) \/S5.6HO#3EJ@$1D MW/.$GSN[;*?UBY=PA3]&CX# Q[U&M5L@D2>FH> PQ <7[KW MC,>Z4<'.,#] 'CLZO!@$>>5+XUMCR%$AQ0I\X7B*.+1B[N-D2BD2+Z33( O1FA_CA>*1;A H$XS'B>5YR%D= MZ0NT-85UBYPW]YOM%6%.4'D$I2)+#^DR8=N38D,&AFWQH657=GX1*;2]2FDU MR++PMDEV!UHGW3]D!Y2WKVLM/7M5Z!8H;]4MG7J&*^^V>$>%T3R[VJ&>P?.R M6\+":M70.LA?9FFM3B%F_?4?,7)PAZ1SZ8HIMTP24)(:8V['%->U?G&&=^YG MF6BZ$^_EJFO[LL6KVN_T,YAI+U 1?%!IF/)[]DP7*S/#XWK+=AEVD&Z M#]<.[JV;9=QH(34_NB_3XC>.].#U8)*YMY:1_]5UM':_,(&=\I#=B1@)%TUF M5X"V$>2N!.I:-SUIHS*Q'GMMYX)[(FDWN'IY M>FV X&P/?KC#;IE/X+#S] '0V^0OF;'T(LK$F67?)'-RUJ79E?<6]P^UP<&+ MQN.NIA\\?2AL;HRWP!I!L: I9$ZN"K)5.;DET5SVWG\(/,L1G@?W]7=@>1;U MQM,HBP&3&O!ZZ1-W5H60FTT^T%K](G@G"QTM77619YX7<,>@4'N-(0P M0T'H<7OQ)K><_:RWM(-T7\1=B<6.=OC8B$;Q[/EC/K5P(@MYJ4W+!R;['$PA M0/[>RQZ9U&X_@Z%!B^9\:,VOUB^)GK*HM#WATVEW^ M$N)).9D5*Z\8DRCNN.MRS*Q0]^V"J>^+^,+S/MV>ULMB\3^_J]XD"0=.Y+LQ MI$,@H.6XX,?)G2<7)H$3;-A,;J3BD6WLCL.Z,*J#KJYVP4.XI:S"'R1/?D\E M0UA -'^E8%G!13K"H*JP.\L?LZ/KSR_G_A[AJM\%2:XPYQ+W:5H8XW;,YV , M=[5>]^G!W&=@"V]F"LYNIU9=+&N)LLXF*^]U=?I:Z_#!/N'/?G+10!NTG^[ MV8;64V"[NUC0;&G(Z)ECN)02BNH'\ I-<0SQ=P#6GDTME] 4Q')9US*P3RA^ MGKN>K@WZA4D;!:.AFV5D9"&3\8XSWZG&N$_M(H?BQG(<&L@YHC],P=Z7V9I& M%IH[]K7#=*NV%R7,^K'% M"85@CRUS4%?JS<[5F^RB84E*B9J^ZPJ;)@WYD@V394*J2JCDG+*C]5L/)CU7 MPJ*P,;/V+&86.&[4>QZ;SFN)5I\4IG^X!J.D%[BOZP].MWEHV'QY-_]@ROY# M6Z_&J!9C:N3Z8:J'U3#5!*=]5PU3W2)95%-)*U;W=."Q@?6GHZ/+>NVCLI' MI/HL.-E3:#E]#0%4E5)NLIK;68P=;(M2':B!C*XXH:[)N4_!"Z&C@-;S<0-.Q=)!\Q6#U1_ M./0)6+&45L=5%TK\UM2U@ JGMO#JM1OAP'=LFQ[ 88I408F>TC\<*YZZ2ZL? M36 [!F?[O]CFWX%\BY3^BTL_OM+8G8B\)P+NV_4Y+..$_"!RF< ^)HH=>$UV M3=Y8"T[^OEY;_>3=5 )XT+[:)6^8DHI"S\(W?%AOU-M+H2D :ZN&;_57+QH-@I<[#0' M5$0?>-'? <_%=\,.3.6=BQN\J QV+6QI///K^6("?YTU.PZ

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